As it aims to become a top choice for healthcare agency-of-record assignments, Imre is reinforcing its cross-functional expertise by appointing two new senior leaders in two priority practice areas — media and medical.
Why is it that some consumer brands grow for a decade or more in existing markets while many others remain “flatish” quarter after quarter? Why is it that some prescription brands are able to retain a disproportionate share of their category even after crossing into OTC space? Why is it that some brands can thrive like this while others do not?
With gene therapies by REGENXBIO and AbbVie, Adverum and others in mid- or late-stage trials, this therapeutic class could soon be an option for this common cause of blindness in the elderly.
The drug, REC-994, was being tested to treat cerebral cavernous malformation, or abnormal collection of small blood vessels that form lesions in the brain, which could cause bleeding in the brain, seizures and paralysis.
The BTK inhibitor showed promise in non-relapsing secondary progressive multiple sclerosis but not relapsing MS. The company said it plans to apply for approval for the former “as soon as possible.”
Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a recombinant version of the virus’ spike protein to elicit protection.